brucellosis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.patients are ?18 years of age with brucellosis 2.diagnosed on the basis of at least 1 of the following criteria: isolation of Brucella species from samples of blood or other fluids or tissues; a ?4-fold increase in the Brucella antibody titer to >1 : 80, revealed by standard tube agglutination, between serum specimens obtained ?2 weeks apart and studied in the same laboratory;or Coombs test =1/160, or Brucella IgG-ELISA >12; Additionally, at least 2 of the following 3.compatible clinical findings must have been present: fever, arthralgias, weight loss, hepatosplenomegaly, or signs of focal disease. 4.Good compliance, voluntary joining this study, having the ability to understand and sign the written informed consent approved by the Ethics Committee.
Exclusion criteria
Exclusion criteria: 1.known or suspected hypersensitivity (or another contraindication) to fluoroquinolones or tetracyclines or rifampin; 2.history of epilepsy or other central nervous disease; 3.history of myasthenia gravis; 4.prior QT elongation or serious heart diseases; 5.pregnant or lactating women,or during the study period,including woman of childbearing age with positive pregnancy test results; 6.severe concomitant disease; 7.body weight of <50 kg; 8.receipt of effective antimicrobial therapy for brucellosis ?6 months before entering the study. 9.patients with complications ,such as endocarditis, spondylitis, or neurobrucellosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical response rates;therapeutic failure rates; | — |
Secondary
| Measure | Time frame |
|---|---|
| relapse rates;adverse reaction rate; | — |
Countries
China
Contacts
Qilu Hospital,Shandong University